Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test any good and bad effects of the study drug,
pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.